skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Datamonitor Healthcare has put together an infographic that gives you a great visual overview of the following:

  • Exactly what the multiple myeloma reimbursement challenges are in the UK
  • Who drives the reimbursement decisions for the NHS
  • The top three regimens used in the first-line treatment of State II/III multiple myeloma patients not eligible for SCT in the US, Japan, France, Germany, Italy, Spain and the UK
  • As well as a Multiple Myeloma RxScorecard that shows the clinical efficacy, safety and use, and economics of both FDA approved regimens and experimental regimens